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Purpose. Relatively few results are available in the literature about the radiation response of unresectable sarcomas in relation to
theirhistology.Therefore,anattemptwasmadetosummarizethepresentsituation.Materialsandmethods.Thisreportisbasedon
areviewoftheliteratureandtheauthor’sownexperience.Adult-typesofttissuesarcomas,chondrosarcomas,andchordomaswere
analyzed. Radioresponse was mainly associated with the degree of tumor shrinkage, that is, objective responses. Histopathologic
responses, that is, the degree of necrosis, are only discussed in relation to radiation treatment reports of soft tissue sarcomas as
a group. Results. Radiation therapy alone leads to major responses in about 50% of lipo-, ﬁbro-, leiomyo-, or chondrosarcomas.
The response rate is less than 50% in malignant ﬁbrous histiocytomas, synovial, neurogenic, and other rare soft tissue sarcomas.
The response rates may increase up to 75% through the addition of radiosensitizers such as halogenated pyrimidines or razoxane,
or by the use of high-LET irradiation. Angiosarcomas become clearly more responsive if biologicals, angiomodulating, and/or
tubulin aﬃnic substances are given together with radiation therapy. Razoxane is able to increase the duration and quality of
responses even in diﬃcult-to-treat tumors like chondrosarcomas or chordomas. Conclusions. The available data demonstrate that
the radioresponsiveness of sarcomas is very variable and dependent on histology, kind of radiation, and various concomitantly
given drugs. The rate of complete sustained remissions by radiation therapy alone or in combination with drugs is still far from
satisfactory although progress has been made through the use of sensitizing agents.
Copyright © 2006 Walter Rhomberg. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Little is known about the quality and duration of objec-
tive responses in diﬀerent sarcomas after deﬁnitive or pal-
liative radiation therapy. The few reports on photon irra-
diation deal mainly with soft tissue sarcomas (STS) as a
group [1, 2]. Radiation therapy alone leads to transient ob-
jective response rates up to 50% and local tumor control
in about 30% of unresectable lesions with radiation doses
in the order of 60 to 70Gy [1–3]. Improvements in lo-
cal control and response rates between 50% and 75% have
been achieved by high-LET irradiation [4–7], the use of ra-
diosensitizerssuchasintravenousbromodeoxyuridine,iodo-
deoxyuridine [8], razoxane [9], or hyperthermia. Slater et al
analyzed 72 patients with unresectable STS and found a re-
lationship between local control rates and so-called malig-
nancy groups based on pathologic diagnosis [1]. The aim
of the present paper is to continue that analysis of the ra-
dioresponsiveness of the main histologic groups of sarco-
mas.
MATERIALS AND METHODS
This review is based on the available literature and on the
author’s own institutional experience gained during studies
of radiosensitizing agents in the treatment of sarcomas from
1972 to 2004. The responses to irradiation of unresectable
primaries, recurrent and measurable metastatic lesions from
adult-type STS, chondrosarcomas,andchordomas wereana-
lyzed;thosefromdesmoids,rhabdomyosarcomas,osteogenic
sarcomas, and Kaposi sarcoma were excluded.
Ourradiationtreatmentwasperformedwithhighenergy
photons using shrinking ﬁeld techniques. Most patients re-
ceived 180–200cGy per fraction, usually ﬁve times a week.
The median total tumor dose was 58Gy (range: 30–70Gy)
forthemostfrequentSTS,60Gy(range:54–65Gy)forchon-
drosarcomas, and 63Gy (range: 54–67Gy) for chordomas.
The sensitizer razoxane was given by mouth at a dose of
125mg twice daily to selected patients according to study
protocols. Drug treatment commenced 5 days before the ﬁrst
irradiation treatment and was continued on radiation days.2 Sarcoma
Deﬁnitionofradiationresponse
Response to irradiation has to be seen from two aspects. Sar-
comas may be radioresponsive or even radiocurable in terms
of cell killing but not responsive in terms of shrinking of
the mass [10, 11]. Brennan et al wrote, “this can be per-
plexing, as such masses could give the false impression that
little has been accomplished, whereas in reality the mass is
mainly made up of sterilized tumor cells and debris” [10].
The degree of tumor cell sterilization (necrosis) may be of
v a l u ew i t hr e s p e c to fl o c a lc o n t r o la n ds u r v i v a l[ 12]. How-
ever, the assessment of the degree of necrosis necessitates
a histopathologic investigation and is, therefore, mostly re-
stricted to neoadjuvant preoperative studies. Moreover, con-
siderable necrosis may preexist in many sarcomas before any
treatmenthasbeengiven.Tobeclinicallyuseful,thedegreeof
pathologic necrosis should reach some 95%. This value was
found to be an independent prognostic factor for local con-
trol and survival [12] .W i l l e t te ta lf o u n dt h a tm o d e r a t ed o s e
preoperative radiotherapy resulted in 80% necrosis in 21 of
27 specimens. Grade and size (>10 versus <10cm) were im-
portant predictors of response to radiotherapy independent
of histologic type [13].
In this review, radiation response will in the main be re-
lated to the extent of objective tumor shrinkage deﬁned ac-
cording to standard criteria. A complete response (CR) re-
quired the complete disappearance of a tumor both clini-
cally and by radiographic imaging. A partial regression (PR)
meant a reduction of the initial tumor volume by more
than 50%, and disease progression (P) was assumed if the
pretreatment tumor volume increased over 25% during or
shortly after the end of the radiotherapy. “No change” (NC)
described a response between PR and progression. Local tu-
mor control was deﬁned as freedom from symptoms and no
regrowth of the tumor at the site of irradiation as long as the
patient survived.
Deﬁnitions of tumor responsiveness are often a matter of
d e b a t e .Ap r o p o s a lc o u l db ea sf o l l o w s :as a r c o m at y p ei sr e -
garded as radioresponsive if the majority of tumors show an
objective regression with a CR rate up to 25% and proven
survival beneﬁts due to adjuvant irradiation. Sarcomas were
designated moderately responsive if less than 50% of the tu-
mors reduced in size in terms of a partial and occasional
complete regression. Resistant sarcomas are associated with
a major objective response rate below 25%, and a majority
of them possibly exhibit progressive disease within 3 months
after the start of radiotherapy.
RADIATION RESPONSE BY HISTOLOGIC SUBTYPE
Fibrosarcomas
In the past, this subtype of STS was more frequently di-
agnosed than today since it probably included some cases
of malignant ﬁbrous histiocytoma or gastrointestinal stro-
mal tumors. There is controversy about the radioresponses
of these tumors. Fibrosarcomas were largely regarded as ra-
dioresistant, especially the subunit of dermatoﬁbrosarcoma
protuberans. This, however, was recently questioned at least
fortheadjuvantsetting[14].Inaddition,almost40yearsago,
Windeyeretaldescribedasatisfactorylocalcontrolbyradio-
therapyintheadjuvantsettingandanobjectiveresponserate
of 50% even in inoperable, recurrent, or residual ﬁbrosarco-
mas [15].
Fibrosarcomaswereoneoftheﬁrstentitiesthatweresub-
jected to irradiation together with the radiosensitizer razox-
ane (ICRF 159) in England. Ryall et al reported an objec-
tive response rate of 73% of STS by radiotherapy combined
with razoxane. The majority of their cases were ﬁbrosarco-
mas [16]. We found an overall response rate of 70% in a pi-
lot series of 10 patients with ﬁbrosarcomas treated with ra-
diotherapy and razoxane between 1973 and 1977. The me-
dian response duration was 8 months. But later, among 8
chemonaive patients with ﬁbrosarcomas subjected to irradi-
ation together with razoxane, there were 5CR and 3PR, and
the median duration of response rose to 15 months empha-
sizingtheinﬂuenceofthepretreatment.Severaltimesastrik-
ing liquefaction of the tumors could be noted clinically. Sub-
group analysis within a randomized study [9] showed that
6 of 7 patients with a ﬁbrosarcoma subjected to irradiation
together with razoxane achieved an objective response (3CR
and 3PR, resp), conﬁrming the results of our pilot study and
the early results of Ryall et al [16]. Thus, the rate of ma-
jor responses in our 17 patients with measurable ﬁbrosar-
comas subjected to irradiation together with razoxane was
76%. For comparison, among 5 measurable cases random-
ized to be treated with radiotherapy alone, we saw 2PR and 3
unchanged tumors. Taken together, there seems to be a clear
improvement of the radiation response rate in the group of
ﬁbrosarcomas also treated with the radiosensitizer razoxane.
Data on a doxorubicin-based chemo-radiotherapy are not
available.
Liposarcomas
Liposarcomas are known to belong to the more sensitive va-
rieties of STS but data on quantitative measurements of re-
missions are sparse. One of the few studies that provided
objective data of the radiation response of myxoid liposar-
coma (MLS) was recently published by Pitson et al [17].
In a series of 16MLS tumor specimens the mean pretreat-
ment and post-treatment volume of the MLS tumors was
415 and 199cm3 corresponding to a reduction in the me-
dian tumor volume of 59%. This result achieved by radio-
therapyalonewasinsharpcontrastto16controlcasesofma-
lignantﬁbroushistiocytomas.Inourownexperience,among
9patientswithliposarcomastreatedwithradiotherapyalone,
there were 2CR, 2PR, 2NC, and 2 progressive diseases, re-
spectively, and one patient was not assessable. The objective
response rate of 50% corresponds approximately to that of
the MLS series of Pitson et al [17].
These 9 patients were part of a randomized study pub-
lished in [9]. In that study, another 9 patients were ran-
domized to receive razoxane together with radiation treat-
ment. The median radiation dose at the tumor site was 55GyWalter Rhomberg 3
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Figure 1: Response of 16 assessable liposarcomas randomized be-
tween radiotherapy (RT) alone and together with razoxane (Rz).
(range: 40–60Gy). Five of 8 assessable patients had a com-
plete response (CR), and 3 had a partial response (PR) cor-
responding to a near 100% response rate. One patient was
not assessable because of a gross residual unmeasurable tu-
mor. Figure 1 shows a late subgroup analysis of 16 assessable
liposarcomas treated within that randomized study. The me-
dianfollow-uptimeofthe16patients(includingthepatients
who died) was 29 months (range: 1.5–110+ months).
Leiomyosarcomas
Leiomyosarcomas (LMS) occur frequently in the uterus,
bowel, vascular tissues, and less commonly in somatic soft
tissue or bone. LMS was proven to be the most frequent sec-
ondarytumorinducedbyradiation.Apartfromcasereports,
there are no large series on the radioresponsiveness of LMS.
Treatment results are usually restricted to the adjuvant set-
ting. With the exception of LMS of the uterus [18, 19] there
is agreement about the necessity and the beneﬁt of postop-
erative radiation therapy in LMS. In sarcomas of the uterus,
LMSwereusuallycomparedtootherentitieslikeendodermal
stromal sarcomas (ESS) and mixed mesodermal sarcomas
(MMS). The deﬁnitive radiotherapy of uterine leiomyosar-
comas is not rewarding. Based on a review of the literature,
none of 10 cases of stage II-IV LMS survived 5 years; the
same was true also for the MMS and ESS varieties [19]. By
combining external beam radiotherapy and brachytherapy,
a n dt o t a ld o s e so f8 0G y ,2C Ro fE S Sb yi r r a d i a t i o na l o n e
were observed by Weitmann et al [20]. Perhaps, LMS of the
prostate may represent a more radioresponsive entity where
cures are possible in the odd case [21, 22].
We treated 9 patients with measurable LMS (primaries
and metastases). Among 4 cases treated with radiotherapy
alone, 2PR, 1NC, and 1 progression were seen leading to an
objective response rate of 50%. The duration of the partial
responses was 3 and 15 months. When razoxane was added
to the radiation treatment in 5 patients, 2CR and 3PR with
a median duration of 22 months was observed, although one
female received salvage surgery. Of course, the small num-
bers of patients preclude ﬁrm conclusions, but the tendency
to improve the radiation response by the combination with
razoxane is seen also in this type of STS.
Malignantﬁbroushistiocytomas
Malignant ﬁbrous histiocytoma (MFH) is a pleomorphic
neoplastic disease withuncertain histological origin. Patients
have an absolute three-year survival rate between 43% and
72% [23, 24]. The prognosis is strongly dependent on tumor
size and the depth of a muscular tumor [24, 25]. Complete
surgical resection at the time of primary tumor presentation
is the treatment of choice, although adjuvant radiation ther-
apy plays an important role in achieving better local con-
trol [25–27]. Responses to primary single and combination
chemotherapy occur in about 30% of the patients [24]. Most
authors feel that radiotherapy alone or chemotherapy is not
eﬀective in MFH.
A literature survey in 1981 revealed that local control was
obtained in only 2 of 16 patients treated by radiotherapy
alone, but measurement of tumor response or details of the
radiation treatment were not well documented [27]. A study
of 16 patients with measurement of the radiation response
in malignant ﬁbrous histiocytomas came from the Princess
Margaret Hospital in Toronto. Fourteen tumors were grade
III-IV, the median time from the pre-RT image to the start
of treatment was 25 days (range: 4–50 days). All patients re-
ceived50Gyin2Gyfractions.Tumornecrosiswasquantiﬁed
in the pathology report after surgery in 10MFH tumors. A
median of 80% of the MFH tumors was necrotic. The mean
pretreatment and post-treatment volume of the 16MFH tu-
mors was 264 and 273cm3,r e s p e c t i v e l y( P = .804) [17].
Thus, the radioresponsiveness of MFH tumors was clearly
less than in 16 comparable cases with myxoid liposarcomas
from the same institution although the observed degree of
necrosis was not diﬀerent [17].
Among 4 of our cases treated with radiotherapy alone,
there were 1 complete response, 1 partial response, and 2
unchanged tumors. Another 4 patients with measurable tu-
mors received irradiation with razoxane, resulting in 2PR
and 2NC with a median duration of 10.5 months. Two fur-
thercasestreatedwithrazoxanehadincompleteresectionsof
masses that were not measurable, but they remained locally
controlled. Summarizing the available data, the radiorespon-
siveness of MFH in terms of tumor shrinkage seems to be
limited. The value of the radiosensitizing agent razoxane re-
mains unclear.
Synovialsarcomas
This entity accounts for approximately 8% of all STS, and it
typically aﬀects the extremities. The translocation (X;18) has
been noted in more than 90% of cases. Synovial sarcomas
(SS) have a higher level of chemosensitivity compared with4 Sarcoma
other STS [28]. They appear to be particularly sensitive to
high-dose ifosfamide chemotherapy [29].
In 1971, Kagan et al observed diﬀerent responses (CR,
PR, and NC) in one patient with multiple metastases of an
SS, dependent on the time/dose/fractionation scheme [30].
An early review from Carson et al in 1981 indicates the exis-
tence of only a few reports on the use of radiotherapy alone
or in conjunction with excision [31]. The authors reported
on their own 36 patients with SS, and underlined the unfa-
vorableoutcomeassoonasthepatientsdevelopedinﬁltrative
tumors of T-3 stage, or if the tumors showed poorly diﬀeren-
tiated histologies. Among 3 macroscopic incomplete resec-
tions in primary SS which were irradiated with 40, 58, and
82Gy, respectively, 2 died of local recurrence after 6 and 24
months, and 1 died from lung metastasis after 6 months, the
primary being controlled. Measurement of the response was
not performed.
Twenty years later, the question as to objective response
rates following irradiation is still not solved but meanwhile
there is a consensus on the need for radiotherapy following
marginal resection. A large series of 271 synovial sarcomas
wasrecentlyanalyzedbyFerrarietal[28].Theauthorsfound
10 cases which remained unresectable after some pretreat-
ment (mostly with chemotherapy), with radiotherapy being
the only local treatment thereafter. Only 1 of 10 survived; re-
sponse data were not given.
Our own experience comprises 7 patients. Three patients
received radiotherapy alone: there were 1 histopathologically
conﬁrmed complete response (bone lesion 5 × 5cm;60Gy),
1 partial response (primary at the knee; 55Gy), and 1 pro-
gressive disease at an R-2 resected primary. The patients sur-
vived 60, 18, and 12 months, respectively. Four patients were
treated with radiotherapy and razoxane by randomization
with 1PR and 3NC. However, 2 of the unchanged lesions
were metastases that received only 30 and 36Gy.
Sarcomasofthebloodvessels
As a rule, angiosarcomas (AS) have a worse outcome in com-
parison to other STS. They usually present high-grade his-
tology and have a high propensity for local recurrence and
distant metastases. However, biology and prognosis are also
dependent on the site of origin. Thus, tumors originating on
the scalp, face, or the thyroid imply a dismal prognosis com-
pared with those in other locations [32–35]. The 5-year sur-
vival is between 0 and 13% especially among patients who
wereirradiatedwithclinicallyevidentdisease[32,33,36,37].
Present studies, however, indicate a 5-year survival of 45%–
60% in all angiosarcoma patients treated with curative intent
[32, 37].
Most frequently, radiotherapy is given as an adjunct to
surgery in the setting of minimal residual disease. Few data
exist about primary or deﬁnitive radiotherapy of AS. Single-
case reports repeatedly describe complete durable responses
with radiotherapy alone [38, 39] but the true incidence of
such an outcome remains unknown, and it is probably lower
than case reports suggest. In a study by Mark et al [40], only
1 of 9 patients (11%) treated with RT+/ −CT was rendered
free of disease. We treated 2 patients with radiotherapy alone
(by randomization): one patient with a recurrent angiosar-
coma of the thyroid measuring 7.5 × 4cm had progressive
disease despite a dose of 60Gy given in 30 fractions. A partial
responsewasseeninametastaticlesionontheforeheadfrom
an AS of the breast irradiated with 14Gy only.
Angiosarcomas emerge as chemoresponsive tumors [41–
43]. Radiation with innovative drug regimens, for example,
cytokines, antiangiogenic substances, and others, seems to
become a promising treatment option [44–46]. Ohguri et al
used rIL-2 immunotherapy together with radiotherapy (me-
dian 70Gy, single fractions 2–3Gy) in 20 patients with an-
giosarcomasofthescalp,15ofthemhadnosurgery.Theme-
dian overall survival time was 36 months; the median local
recurrence-free survival 11 months. Local recurrences were
observed in 7 patients only (35%) [44]. These results were
more favorable than any previous report in the reviewed lit-
erature [44]. Unfortunately, objective response data are lack-
ing in the article.
We used radiotherapy together with razoxane in 3 pa-
tients with unresectable AS on the scalp, the heart, and
the lung, respectively. The radiation doses were 66, 30, and
40Gy. All 3 patients responded partially, 2 with a subtotal re-
gression of their primaries. Distant metastases were the lim-
iting event in all 3 cases associated with survival times of 15,
9, and 8 months, respectively.
In an ongoing study of the Austrian Society of Radioon-
cology (¨ OGRO), using radiotherapy in combination with ra-
zoxaneandvindesine,atubulinaﬃnicantiinvasivesubstance
[47], 3 of 7 patients with measurable angiosarcomas showed
a CR, 3 had a partial response, and 1 did not change (minor
response). The complete responses occurred at unfavorable
sites like the thyroid, chest wall, and scalp. No recurrences
were seen in the responding patients after a median follow-
up time of 17+ months for the living patients (Wink et al,
preliminary observations).
The value of radiotherapy in the management of hem-
angiopericytomas (HPC) has changed. Earlier discussed as
controversial, surgery and postoperative radiotherapy are
now favored as initial procedure by the majority of authors
[48, 49]. Again, little is known about the responses in case of
unresectable, gross residual, or recurrent tumors. A review
by Schier et al covering a period from 1942 to 1987 iden-
tiﬁed 14 cases of HPC that were treated with radiotherapy
alone. There was a fatal outcome in 91% of the cases, mostly
around 3 years. Nine cases received no treatment at all: all of
them died, 85% after a mean time of 2–3 weeks only [50]. In
the experience of the University of Iowa College of Medicine,
only one of seven patients initially treated with surgery alone
has remained continuously free of disease. In contrast, all
four patients treated with surgery and postoperative radia-
tion therapy have remained alive with NED despite the fact
that three of these patients had gross residual tumor at the
time of irradiation [49]. Altogether, 10 of their 15 patients
received radiation therapy at some stage of the management.
Local tumor control was achieved at all sites receiving greater
than 5500cGy. Similar results were obtained at the MD An-
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In our institution, a recurrent HPC on the meninges (tu-
mor volume about 4–5ml) disappeared completely after ra-
diotherapy alone with 60Gy. The patient is alive without ev-
idence of disease 20 years later. Adding razoxane to the ra-
diation treatment has resulted in 3 of 3 patients showing a
partial response for a median time of 10 months. Adding ra-
zoxane and the vinca alkaloid vindesine to the radiotherapy
has given partial responses in 3 of 3 assessable tumors for a
median time of 24+ months; 1 additional patient with non
measurable residuals at the spine remained recurrence-free
40+ months.
Chondrosarcomas
Chondrosarcomas (CS) are frequently termed as radioresis-
tant but measurements of the response are rarely presented.
Location as a factor of prognosis has to be considered in the
judgement of the disease. For instance, chondrosarcomas of
the larynx must be seen as an own entity with a favorable
prognosis [51, 52]. Likewise, chondrosarcomas of the base of
the skull show favorable outcomes if protons or heavy ions
were used for irradiation [53, 54]. In contrast to the ma-
jority of the literature, however, there are single reports of
high local control rates of incompletely resected chondrosar-
comas even at the spine and pelvic bones [55]. The authors
assumed that the impression of frequent radioresistance is
due to a tendency of these tumors to regress slowly and the
persistence of skeletal destructions often seen in X-rays. In
addition, low radiation doses were used in some earlier re-
ports.
More exact data on the response of chondrosarcomas are
found in studies which compared conventional photon irra-
diation with neutrons. Laramore et al reported an objective
response rate (CR + PR) of 33% with photons versus 49%
with neutrons [56]. In the experience of McNaney et al only
1 of 7 patients treated with photons alone remained locally
controlled [57].
Chondrosarcomas are regarded as not responsive to cy-
totoxic chemotherapy regardless whether it has been given
alone or in combination with radiation treatment. The only
report of an improvement of the radioresponsiveness of
chondrosarcomas by chemical substances came from Eng-
land: in 1979 Ryall et al reported a complete and partial re-
sponse rate of 62% when radiotherapy was combined with
the sensitizer razoxane [58].
Stimulated by these observations, we undertook a long-
term study to explore the radioresponsiveness of these rare
tumors using the protocol of Ryall et al. Between 1984 and
2003, 13 patients with chondrosarcomas were subjected to
irradiation together with razoxane. Eight patients had un-
resectable primaries or recurrences, and 5 received post-
operative irradiation (one R-0 and four R-1 resections).
The median radiation dose was 60Gy (range: 54–65Gy),
the median dose of razoxane was 8.5grams (range: 6–
15g).
Among 8 unresectable or recurrent chondrosarcomas
with measurable disease, there were 1 complete and 5 partial
regressions, and 2 tumors did not change. The overall re-
sponse rate was 75%, the median duration of response 23
months. Although 4 of these 8 patients were not locally
controlled, the median survival time is not yet reached and
liespresentlyat45+months(Table 1).Threeofthe4patients
without clear surgical margins remained locally controlled.
They survived up to now 12, 21+, 48+, and 160+ months,
respectively. One patient with clear margins remained free of
disease 87+ months; he had no further follow up. Overall,
local control was achieved in 7 of 12 patients who were not
radically resected.
Apart from the patients treated with razoxane, 2 other
patients received radiation therapy alone by randomization.
One of them had no clear margins at surgery, and the other
had a recurrence, size 8 × 8cm. The recurrent tumor pro-
gressed even during the radiotherapy. The two patients sur-
vived 7 and 9 months, which was the shortest survial of all of
our patients with CS.
Chordomas
Conventional megavoltage irradiation with a median dose
of 50Gy leads to a local control rate of 27% in chordo-
mas [11], while objective tumor regressions are rarely de-
scribed. For instance, in a recent series of 18 patients with
skull base chordomas treated with spot scanning proton
b e a mt h e r a p y ,n oc o m p l e t eo rm a j o r( >50%) response was
observed [59]. The median time to recurrence or symp-
toms is 3.5 years in patients with residual disease [60]b u t
sometimes also less [61, 62]. Freedom of symptoms af-
ter 10 years was seen in less than 10% of the cases from
Zurich [63], and no patient survived 10 years among 4 pa-
tients receiving radiotherapy alone in a series of 21 pa-
tients of Keisch et al [64]. Therefore, several authors came
to the conclusion that inoperable or gross residual chordo-
mas can rarely be cured by conventional irradiation with
photons [60, 61, 63]. By using protons or heavy ions, the
local control rates rose to around 60% to 70% [6, 59,
65].
Wetreated5consecutivepatientswithunresectablechor-
domas at the spine (3 cases) and the base of the skull (2
cases) with radiation and razoxane [66]. The more favor-
able chondroid variant of chordomas was excluded by a
secondary pathology review in all but one case. The me-
dian radiation dose was 63Gy (range: 54–67Gy); the me-
dian total dose of razoxane was 7.6 grams (range: 5.4–
11.5g).
Among 4 measurable tumors there were 2CR, 1PR, and
1NC. All 5 patients survived 5 years and remained locally
controlled for 5, 7+, 6.4, 13+, and 15+ years. After a po-
tential median follow-up time of 10 years, 3 of 5 patients
are alive without evidence of disease proven by CT and MR
imaging. The treatment had little toxicity. Mucosal reactions
were predominant as the local side eﬀects, 2 of the 5 pa-
tients showed a grade 3 leukopenia (WHO) due to razox-
ane. So far, no late toxicity at the CNS or the optic nerve was
observed.6 Sarcoma
Table 1: Radiotherapy and razoxane in 8 patients with unresectable primary or recurrent chondrosarcomas.
#A g e / g e n d e r
Deﬁnitive irradiated tumors Results of radiotherapy + Rz
Remarks
Primary Size (cm) Grade Response Duration Local Survival
(months) control (months)
1 61/m Os ileum 20 ×15 G1 PR 20 No 38 Died from local recurrence
2 58/m Larynx 5 ×4G 2PR 85 Yes 85 Intercurrent death
3 74/f Groin 17 ×11 G3 PR 22 Yes 22 Lung metastasis
4 80/f Knee 15 ×14 G2 PR 90 Yes+ 90 + Sekund amputation
5 24/f Orbita 0.8 ×0.8G 2 CR 48 No 56+ Salvage surgery after 48 months
6 65/m Sternum 3 ×2G 1NC 25 No 52+ Salvage surgery after 25 months
7 44/f 2nd rib 8 ×8G 2NC 22 Yes∗ 22 ∗ No follow-up last 5 months
8 81/m Humerus 6 ×5, 4 × 3G 2 PR 16 No 28+ Regrowth after 16 months
Neurogenicsarcomas/malignantschwannomas
Because of the rarity of these tumors there is no data on
larger series concerning their radio-responsiveness. Five of
our patients with malignant schwannomas received deﬁni-
tive radiation treatment, 2 with radiation alone and 3 with
radiation and razoxane. With radiotherapy alone we ob-
served one unchanged and one progressive tumor; with ra-
diotherapy and razoxane there was 1PR (25Gy) and 2 un-
changed tumors. So far, the radioresponsiveness of neuro-
genic sarcomas cannot be judged; for the present it seems to
be low. This is in accordance with the experience of Raney et
al: none of 12 children with gross residual disease survived 3
years;andtheauthorsstresstheneedformoreeﬀectivetreat-
mentprogramsespeciallyforthosewithunresectabletumors
[67].
Miscellaneousothersarcomas
The current knowledge concerning deﬁnitive radiotherapy
for various rare sarcoma entities such as clear cell, alveo-
lar soft part, or epithelioid sarcomas is restricted to occa-
sional case reports. Therefore, no clear picture is evolving
from those data but there is the impression of a rather lim-
ited radioresponsiveness. Ferrari et al on behalf of the Ital-
ian and German Soft Tissue Sarcoma Cooperative Group re-
ported on 28 pediatric patients with clear cell sarcoma. Eight
patients received radiotherapy postoperatively. The only two
irradiated patients with gross residual disease after surgery
“did not respond signiﬁcantly.” The authors concluded that
radiotherapy may control microscopic residual disease af-
ter surgery, chemotherapy is ineﬀective, and the prognosis is
unfavorable for patients with unresectable and large tumors
[68]. Shimm and Suit treated 2 epithelioid sarcomas with ra-
diotherapy alone. Both tumors did not change in their size,
only 1 was locally controlled, and both cases developed dis-
tant metastases [69]. A partial remission and an unchanged
tumor was observed in two of our own cases with alveo-
lar soft part sarcomas treated with radiotherapy and razox-
ane. Both cases remained locally controlled after radiation
doses of 40 and 30Gy but died from distant metastases after
9 months and 6 years.
DISCUSSION
The terms radioresponsive and radiosensitive are synony-
mous in everyday usage. It will be diﬃcult to associate objec-
tive responses exclusively with “radioresponsiveness” and the
degree of tumor necrosis with the generic term “radiosen-
sitivity”. In reporting on deﬁnitive radiotherapy, it should
however be suﬃcient to describe the quality and degree of
objective responses and their duration, local control, and
survival. Those data would speak for themselves and cover
radiosensitivity (histopathologic necrosis) and radiorespon-
siveness (shrinking of a mass) as well. Knowledge about the
radioresponsiveness of sarcomas is of value for treatment de-
cisions, forexample, a good response may more likely permit
the conservative surgical excision of tumors of borderline re-
sectability, or for having data to be compared with results
from novel treatments.
The radioresponsiveness of sarcomas as a group is mod-
erate at best. About 40%–50% of the tumors show tran-
sient objective responses to radiotherapy alone; complete re-
sponses are less frequent. Some reports deal with histopatho-
logic response rates, that is, the degree of tumor necrosis [12,
13, 70, 71], but the prognostic signiﬁcance of a 60% to 90%
tumor necrosis, values most frequently observed, remains
unclear. As mentioned, several measures led to an increase of
local control and objective responses in sarcomas. Interest-
ingly, the use of contemporary cytotoxic chemotherapy rep-
resented by doxorubicin-based regimens together with con-
comitant radiotherapy seems to be of low or modest eﬃ-
cacy. A study with neoadjuvant doxorubicin-based chemo-
radiation in STS revealed a tumor-downstaging in 18% of
patients only although there was a survival gain [72]. An-
other work reported no radiographic partial response or dis-
ease progression among 27 patients but there were some his-
tologic responses in the series [71]. The amount of necro-
sis was dependent on the doxorubicin dose given together
withradiotherapy.Eilberetalreportedonneoadjuvantcom-
binedtreatmentsforhigh-gradeextremitySTS.Majornecro-
sis increased to 48% with the addition of ifosfamide as com-
pared to 13% of the patients in all other protocols combined
[12]. In a study using preoperative radiotherapy together
with the MAID regime (MAID = mesna, adriamycin, ifos-
famide, dacarbazine), DeLaney et al saw no clinical completeWalter Rhomberg 7
responses and 10.6% partial responses among 48 patients; 36
patients (75%) did not respond [70]. Six patients (13%) had
radiographic evidence of “progression” by tumor measure-
ments on the MRI scans. Most of the tumors in these 6 pa-
tients, however, showed pathologically conﬁrmed necrosis of
various degree. The authors suggested that the radiographic
progression represented swelling of tumor secondary to the
osmotic eﬀect of necrosis [70].
This overview indicates that the radiation response of
sarcomas is dependent on the histopathology and the addi-
tion of chemical modiﬁers of the radiation response. Radio-
therapyaloneleadstomajorbuttransientresponsesinabout
50% of lipo-, ﬁbro-, leiomyo-, or chondrosarcomas. The re-
sponse rate is less than 50% in malignant ﬁbrous histiocy-
tomas, synovial sarcomas, neurogenic sarcomas, and other
rareentities.Nodeﬁniteconclusionsareallowedforthelatter
forms since the available data are sparse. The response rates
may be increased to 75% by the use of chemical modiﬁers.
In particular, angiosarcomas showed promising responses
if biologicals, angiomodulating, and/or tubulin aﬃnic sub-
stances are given together with radiation therapy.
The radiosensitizing agent razoxane is able to increase
the duration and quality of responses in ﬁbro-, lipo- and
leiomyosarcomas compared to irradiation alone. Even in
diﬃcult-to-treat tumors such as chondrosarcomas or chor-
domas, photon irradiation together with razoxane induces
objective responses in the majority of patients. Compared to
data from the literature, this treatment combination oﬀers
an alternative to high-LET irradiation. Although the small
number of chordomas precludes far-reaching conclusions,
the fact of nonselected cases, the longer follow-up, and the
favorable responses would make it worthwhile to test razox-
ane together with or against a radiation therapy with protons
or heavy ions.
Razoxane is a largely neglected radiosensitizer which has
an interesting spectrum of modes of action. It is of value in
the treatment of STS because of its proven radiosensitizing
eﬀects [9, 16, 73] and its potential to normalize pathologic
tumor blood vessels [35, 74, 75]. This angiometamorphic
mode of action commends the drug especially for its use in
angiosarcomas. In addition, the drug induced a growth rate
slowdown oftransplantedtumors[76],and thedevelopment
of distant metastases to the lungs was completely suppressed
in preclinical trials [74, 75, 77]. Razoxane is also antiinvasive
[33],anditinhibitsthetopoisomeraseII[78].Unfortunately,
since 2004 razoxane has been discontinued by Cambridge
Laboratories (UK). It is to be hoped that another pharma-
ceuticalcompany willshortly takeup againthe uniquepossi-
bilities of the drug. Meanwhile, the use of dexrazoxane could
be a reasonable alternative. From our experience with radio-
therapyplusrazoxaneinSTS,itwouldseemtobemandatory
in any phase III trial of a new combination to use radiation
and razoxane as the control arm.
This report may represent a ﬁrst inventory of radiation
responses in subunits of sarcomas. It might be of value to
those who intend to analyze new radiosensitizers or novel
combination chemotherapies in conjunction with radiation
treatment. Simple pilot trials with new drugs are needed
since the rates of complete sustained regressions in diﬀerent
sarcomas achieved by the concomitant use of chemical mod-
iﬁers and irradiation are still far from being satisfying.
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